Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6014004 | Epilepsy & Behavior | 2011 | 7 Pages |
Abstract
⺠Carisbamate is a novel drug in development for treatment of seizures and neuropathic pain. ⺠Three controlled, multiple-dose, phase I crossover studies were conducted. ⺠Cognitive effects were assessed in healthy volunteers treated for 5-9 days. ⺠No clinically significant adverse cognitive effects were observed at doses < 1000 mg/day. ⺠Effects were mild to modest at the higher doses tested.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Kimford J. Meador, H.R. Brashear, Frank Wiegand, Peter Zannikos, Gerald Novak,